(Reuters) – Amgen Inc (AMGN.O) on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus.
FILE PHOTO: An Amgen sign is seen at the company’s office in South San Francisco, California October 21, 2013. REUTERS/Robert Galbraith/File Photo
It also maintained its earnings forecast for the year, citing continued growth in sales of new drugs despite the ongoing pandemic.
Oral drugs like Otezla have benefited from coronavirus fears that have kept patients away from rival medicines that must by administered